Citation Impact
Citing Papers
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
2014 StandoutNobel
Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization
2005 StandoutNobel
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
2011 Standout
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
2008 Standout
CD8+CD205+ Splenic Dendritic Cells Are Specialized to Induce Foxp3+ Regulatory T Cells
2008 StandoutNobel
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
2008
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Gastric cancer
2016 Standout
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
2008
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
2008
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
2009
AGA technical review on nausea and vomiting
2001
Pancreatic cancer
2004 Standout
Platinum-based chemotherapy in metastatic breast cancer: current status
2003
Pancreatic cancer
2020 Standout
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting
2000
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
2007
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
2004 Standout
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Head and neck cancer
2008 Standout
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies
2008
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Systemic inflammation, nutritional status and survival in patients with cancer
2009
Pancreatic cancer
2016 Standout
Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis
2001
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self
2005 StandoutNobel
Pancreatic Adenocarcinoma
2014 Standout
Regulatory T cells, tumour immunity and immunotherapy
2006 Standout
The Functional Gastrointestinal Disorders and the Rome III Process
2006 Standout
Cellular processing of platinum anticancer drugs
2005 Standout
Oesophageal carcinoma
2013 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
Regulatory T cells in transplantation tolerance
2003 StandoutNobel
Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review
2003 Standout
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Platinum Compounds in the Treatment of Advanced Breast Cancer
2001
Adjuvant therapy in pancreatic cancer: historical and current perspectives
2003
Gastric cancer
2020 Standout
Role of gemcitabine in cancer therapy
2005
Pancreatic Cancer
2010 Standout
5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
2011
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model
2008
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
2003
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Pancreatic cancer
2011 Standout
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
2005
Naturally Arising CD4+Regulatory T Cells for Immunologic Self -Tolerance and Negative Control of Immune Responses
2003 StandoutNobel
Head and Neck Cancer
2020 Standout
Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor
2008
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
2007
Randomized phase II /III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS ‐PC Study
2015
Direct Expansion of Functional CD25+ CD4+ Regulatory T Cells by Antigen-processing Dendritic Cells
2003 StandoutNobel
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
1999
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
2006
Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function
2002
Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells
2005 StandoutNobel
Dendritic cells expand antigen‐specific Foxp3+CD25+CD4+ regulatory T cells including suppressors of alloreactivity
2006 StandoutNobel
Dendritic cells are specialized accessory cells along with TGF-β for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3− precursors
2007 StandoutNobel
Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study
2005
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence
2000
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
2013 Standout
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
2006
Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001
2008
Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis
1995
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
2003 Standout
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Clinical Translation of Nanomedicine
2015
Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology
2005
Works of Antonio Testa being referenced
Ondasetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial
1994
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2
1998
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule: Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.)
1996
Methotrexate, Vinblastine, Epidoxorubicin, and Bleomycin as Second-Line Chemotherapy for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
1994
Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial
1995
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
2007
Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer
1997
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
2002
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma
2002